flumatinib + imatinib
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelogenous Leukemia, Chronic
Conditions
Myelogenous Leukemia, Chronic
Trial Timeline
Aug 1, 2011 → Dec 1, 2014
NCT ID
NCT01503502About flumatinib + imatinib
flumatinib + imatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Myelogenous Leukemia, Chronic. The current trial status is unknown. This product is registered under clinical trial identifier NCT01503502. Target conditions include Myelogenous Leukemia, Chronic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01503502 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Myelogenous Leukemia, Chronic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bisantrene | Race Oncology | Phase 2 | 44 |
| Bisantrene + Fludarabine + Clofarabine | Race Oncology | Phase 2 | 44 |
| Milademetan + AZA + Milademetan | Daiichi Sankyo | Phase 1 | 33 |
| micafungin + posaconazole | Astellas Pharma | Approved | 85 |
| decitabine Induction Chemotherapy + Induction Chemotherapy | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Gemtuzumab ozogamicin | Eisai | Phase 2 | 52 |
| Ondansetron + Palonosetron | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2/3 | 65 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| ABT-199 | AbbVie | Phase 2 | 52 |
| Posaconazole + ABT-199 + Decitabine + Azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Cytarabine | AbbVie | Phase 1/2 | 41 |
| AZD4877 | AstraZeneca | Phase 1 | 33 |
| MK-8776 + Cytarabine | Merck | Phase 1 | 33 |
| MK0457 | Merck | Phase 1 | 33 |